Patent intelligence · US
US 10071095
1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders
1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders
Patent details — US 10071095
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 11, 2018
- Expiration
- Sep 6, 2038
- Applicant
- Addex Pharma, S.A.
- Claims
- 19
- CPC classes
- A61K, A61K31/437, A61K31/438, A61K31/4545
Quick answer
US 10071095 (1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders) is held by Addex Pharma, S.A.. Status: granted. Granted Sep 11, 2018. Expires Sep 6, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Addex Pharma, S.A.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/437, A61K31/438, A61K31/4545, A61K31/496, A61K31/506
More from Addex Pharma, S.A.
Related pharmaceutical patents in our USPTO index.
-
US 11071729
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
granted -
US 9938270
Mono-phosphate salt of 6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2A]pyridine (dipraglurant) and polymorphs thereof as negative allosteric modulator of MGLU5 receptor
granted -
US 9765091
Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors
granted -
US 9737533
1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
granted -
US 9266834
1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
granted -
US 9226930
1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
granted -
US 9132122
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
granted
Frequently asked questions
What is US patent 10071095?
US 10071095 (1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders) is held by Addex Pharma, S.A.. Status: granted. Granted Sep 11, 2018. Expires Sep 6, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10071095?
Addex Pharma, S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.
When does US 10071095 expire?
Our index shows an expiration date of Sep 6, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.